Clarity Pharmaceuticals Ltd
CU6
Company Profile
Business description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Ask the analyst: Is the market underestimating Bapcor?
This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
stocks
Is our ASX best idea still attractive after shares surge?
Shares rose over 21% following the results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,751.60 | 4.00 | 0.05% |
| CAC 40 | 8,016.35 | 10.13 | 0.13% |
| DAX 40 | 21,964.83 | 53.09 | 0.24% |
| Dow JONES (US) | 44,470.41 | 167.01 | 0.38% |
| FTSE 100 | 8,775.05 | 7.25 | 0.08% |
| HKSE | 21,294.86 | 227.12 | -1.06% |
| NASDAQ | 19,714.27 | 190.87 | 0.98% |
| Nikkei 225 | 38,801.17 | 14.15 | 0.04% |
| NZX 50 Index | 12,917.45 | 41.10 | 0.32% |
| S&P 500 | 6,066.44 | 40.45 | 0.67% |
| S&P/ASX 200 | 8,484.00 | 1.20 | 0.01% |
| SSE Composite Index | 3,318.06 | 4.11 | -0.12% |